Overview

Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anaemia Due to Angiodysplasias

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether long-acting octreotide is effective in the treatment of patients with refractory anaemia due to angiodysplasias. The hypothesis is that long-acting octreotide is effective in decreasing the blood and iron infusion requirements in those patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Radboud University
Collaborators:
Bernhoven
Bernhoven Hospital
Catharina Ziekenhuis Eindhoven
Elisabeth-TweeSteden Ziekenhuis
Gelre Hospitals
Jeroen Bosch Ziekenhuis
Reinier de Graaf Groep
St. Antonius Hospital
VU University Medical Center
Treatments:
Octreotide